Clinical Pathways

Acute Management of Migraine and Migraine-Like Headache

Rahul Shah, MD Henry Chicaiza, MD Eric Hoppa, MD









What is a Clinical Pathway?



An evidence-based guideline that decreases unnecessary variation and helps promote safe, effective, and consistent patient care.

Objectives of Pathway



- To facilitate provider comfort in managing migraine-like headache through standardization of therapy, including second line agents
- To improve emergency department throughput of patients who present with migraine-like headache
- To standardize care of children with migraine-like headache, both in the emergency department and upon disposition

Why is this pathway necessary?



- New guidelines by the American Academy of Neurology published in 2019
 - Incorporation of sumatriptan NS
- Variation in provider practice
 - Use of prochlorperazine, metoclopramide, ondansetron, among others
- Unclear discharge planning
 - O Which patients might benefit from admission?
 - With whom should patients with migraine headache refractory to initial outpatient management follow up?

Background



- Migraines: common reason for ED presentation
 - Most common cause of acute and recurrent headache in children and adolescents
 - Estimated 1% of all visits; translates to over 600 annual evaluations at CT Children's annually
 - Inpatient admissions: between 3-32%
- High morbidity
 - o Depression
 - Decreased quality of life
- Large variability in practice
 - Intravenous normal saline, metoclopramide, prochlorperazine, promethazine, ondansetron, diphenhydramine, non-steroid analgesic drugs, steroids and triptans

This is the Acute Management of Migraine and Migraine-Like Headache Clinical Pathway.

We will be reviewing each component in the following slides.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT

Industre Orbeita. Palients age 36 years presenting with headadhe (194) lasting 2-72 hears with ut incecome of the following dramatoristics: (3) non-occipital location; (2) polisating quality; or (3) aggravated by or causing avoidance of routine physical activity AND in fear now of the following: mane a vomiting photophobia, photophobia. Patients must have a previous similarly described be adache with relief from companyile must attent numual saline halos, non-specialal anti inflammatory drug (MSAED), and/or anti-documentic agent. Balladan Offeria: Age 🗠 years, abrumad neurologic esam, pregramoy, cardiovascular disease, uncontrolled hapertension, intracrunial duarr, lever, malignancy, riosed head. ry/trauma villain 24 hours, concuston villain 2 souths, winner, cancern for increased intracatal pressure/Corbing Titlet, subbor-oracl te adacter conditing models intensity within 5-minutes. Triff of Evolution Mursing Interventions to occur immediately upon rooming patient: Determine feradactiv (NA) pain some using Wong Baker (ACES Fain Rating Scale or Nameric Pain Rating Scale) tights and I'V off; messurage not using electronic devices Determine and document last dose of RSAID and acclaminishin Determine and document last dose of any other medications given to about headache Obtain POCT urine b-HCG for all femalescage 11 or grouter Headache Pain Score Use Worp-Baker Mc-Bratisms. EACES Poin Bating Surrantipten N - Erick administrated in part 2 book AND on contrandications (August die A) Scale or Humanic c 30 kg: 5 mg (max 30 mg/day) Fair Rating Scale 30-59.9 kg: 30 mg/may 20 mg/day) Evoluate 6% poin 40 kg: 20 mg (max 30 mg/stay) score di minsafo (foliose appropriate h.SAE) has not been given with the fast 6 bouts: AddituprofenPO 10 mg/kg mar 600 mg if able to tale rate 70 consistion of each intervention Discharge gout Other Corsidered one repeat 195 pain ware is 450% of the initial pain Record headable core* - 6 minutes after completion of above interventions SCORE! Isthis reassessment HA score (truck ethical basis with 2004) TOTOCHARGE Mace PM Ohrharge Offeria Medications/kydration Pain from headache is \$50% of the Julist HA pain cover NS botte IV 20 mt/kg (mar 1 t) x 1 Prochlorperatine IV 0.15 mg/lg terax 30 mg/ st. 6 deuts after last 1,5000: Discharge Instructions: Ketoediac (V.0.5 ma/km/max 15 martial) Establish plan for patient to follow up with PCP within 48 hours If partiest tips exchappeous that symposium (Myschooks, plast links, confine dyskinesia, Encentage PCP refersal to Neurology if: doned speed by Patient has failed a daily presentative medication for at least Ennsider diphertrydramene PO 1 mg/kg (man 50 mg) x3 Witte: "Fer Correction Children's Headache Pathoyay, pleas strongly coefficier referral to Pediatric Neurology hassessheadache sorre² 45 minutes after completion of above intercernisons Encourage PCP referral to Pain Team Headache Clinic III: If patient has bale down date preventative medications for at feast 12 weeks each OE purient back emprecisedly evaluated by the paintness for any properse in the use assessment into acore dixterps: (50% of the inhiol headadhe sons) Write: "Per Connectical Children's Headache Pathway please strong consider referral to Pain Team's Headache (Bric Repeat NS bole s 20 migNg trix 1 (mai 11) Magnesium sulfate IV 30 rog/kg (mox 2g) Processors have been active score. 45 m instances after completion of above improventions. build any appropriate HA wines (50% of the initial headache soors discharge. Admit to Impatient units. Consell: Neurology to determine to which service patient sheefel be admitted

CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MO



800% benedical conservations cover as light reserved. Nation

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT

Inclusion Criteria: Patients age ≥6 years presenting with headache (HA) lasting 2-72 hours with at least one of the following characteristics:

(1) non-occipital location; (2) pulsating quality; or (3) aggravated by or causing avoidance of routine physical activity

AND at least one of the following: nausea, vomiting, photophobia, phonophobia.


Patients must have a previous similarly described headache with relief from comparable medications [normal saline bolus, non-steroidal anti-inflammatory drug (NSAID), and/or anti-dopaminergic agent]

poors trained out trapert Argust Farter as hare reasonal 18 pbs

Exclusion Criteria: Age <6 years, abnormal neurologic exam, pregnancy, cardiovascular disease, uncontrolled hypertension, intracranial shunt, fever, malignancy, closed head injury/trauma within 24 hours, concussion within 2 months, seizure, concern for increased intracranial pressure/Cushing Triad, sudden-onset headache reaching maximum intensity within 5 minutes.

It is important to note that only patients that meet these specific criteria can be managed like migraines.

The presence of any concerning features, such as fever, injury and seizures, are concerning for an alternative etiology and should be evaluated and treated off pathway.





CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CUNICAL JUDGMENT

Industry Otheria: Polinets age by year spreading with headadre (HM) is dring 7-22 hear width of incorone of the following drawatoristics:

(3) non-original discriber; (2) and other quadity; or (3) agreement for or covering anotherine or coroning phosphale, antivity:

(4) Go to be accorded the following manure, counting, phosphale, phosphales, antivity:

(5) Agreement have a previous similarly described the adades with midd from comparable mediations.

(6) James 15 allowing manure, counting the color of the comparable mediations of the comparable mediation before the counting of counting (4) agreement the control of the comparable mediations of the counting of counting (4) agreement the counting of counting (4) agreement the counting of the


Initial Evaluation

Nursing Interventions to occur immediately upon rooming patient:

- Determine headache (HA) pain score using Wong-Baker FACES Pain Rating Scale or Numeric Pain Rating Scale¹
- Lights and TV off; encourage not using electronic devices
- Determine and document last dose of NSAID and acetaminophen
- Determine and document last dose of any other medications given to abort headache
- Obtain POCT urine b-HCG for all females age 11 or greater

Upon rooming the patient, nursing interventions include pain evaluation, controlling potential environmental triggers, and obtaining information on when medications were given last.

This will allow for accurate timing of additional medications, and avoid over (or under) medicating the patient.



CONTACTS: RAHUL SHAH, MD | HENRY CHICALZA, MD | ERIC HOPPA, MD





¹ Headache Pain Score

- Use Wong-Baker FACES Pain Rating Scale or Numeric Pain Rating Scale
- Evaluate HA pain score 45 mins after completion of each intervention
- Discharge goal: repeat HA pain score is ≤50% of the *initial* pain score

CLINICAL PATHWAY: Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL BIDGMENT


Initial Evaluation

Nursing Interventions to occur immediately upon rooming patient:

- Determine headache (HA) pain score using Wong-Baker FACES Pain Rating Scale or Numeric Pain Rating Scale¹
- Lights and TV off; encourage not using electronic devices
- Determine and document last dose of NSAID and acetaminophen
- Determine and document last dose of any other medications given to abort headache
- Obtain POCT urine b-HCG for all females age 11 or greater

Note that pain scores are evaluated using either the Wong-Baker FACES Pain rating scale, or the Numeric Pain Rating Scale.

After a baseline pain score is determined, routine evaluations will occur 45 minutes after completion of each intervention outlined. This will allow providers to determine if pain is being appropriately managed.





poors traineritual compress asseguis frantes as rights received. 1 6 pts



Intranasal sumatriptan and NSAIDs have the best evidence for acute migraine management, and are utilized as the primary interventions here.

Sumatriptan can be used as long as no contraindications exist.

Appendix A outlines contraindications to Sumatriptan use.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CUNICAL DIDEMENT

Initial Management

Medications:


- Sumatriptan IN if not administered in past 2 hours AND no contraindications (Appendix A)
 - < 30 kg: 5 mg (max 10 mg/day)</p>
 - o 30-39.9 kg: 10 mg (max 20 mg/day)
 - ≥ 40 kg: 20 mg (max 30 mg/day)
- If dose appropriate NSAID has not been given with the last 6 hours:
 - o Add Ibuprofen PO 10 mg/kg, max 600 mg, if able to tolerate PO

Other Considerations:

Oral rehydration

As ses sment:

Reassess headache score 45 minutes after completion of above interventions



History of organ transplant
 Use of another 5HT1 agonist (other than sumatriptan) or ergotamine derivatives within the last

Severe hepatic impairment

Uncontrolled HTN

Stroke

Use of MOA-I in past 2 weeks

CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIG HOPPA, ME



\$5079 Technical Content Areas Street, All light reserved. Nabel

In addition, oral rehydration can be initiated.

It is important to reassess the headache score 45 minutes after these interventions.

¹ Headache Pain Score

- Use Wong-Baker FACES Pain Rating Scale or Numeric Pain Rating Scale
- Evaluate HA pain score 45 mins after completion of each intervention
- Discharge goal: repeat HA pain score is ≤50% of the *initial* pain score

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CUNICAL JUDGMENT

Industry Different age ob year spreading with headache (194) before 2-72 hear widther index one of the following distraction as:

(1) non-original Acotions (2) poll-dusing quadro, or 151 approvated by or counting prospection of motive physical activity

(8/DL or hear new of the Moderney maney, accounting phospholists, phospholists, activity)

(8/DL or hear new of the Moderney maney, counting phospholists, phospholists, and control or the Moderney maney and the Moderney maney of the Moderney maney of the Moderney maney of the Moderney of

Initial Management

Medications:


- Sumatriptan IN if not administered in past 2 hours AND no contraindications (Appendix A)
 - < 30 kg: 5 mg (max 10 mg/day)
 </p>
 - 30-39.9 kg: 10 mg (max 20 mg/day)
 - \circ \geq 40 kg: 20 mg (max 30 mg/day)
- If dose appropriate NSAID has not been given with the last 6 hours:
 - Add Ibuprofen PO 10 mg/kg, max 600 mg, if able to tolerate PO

Other Considerations:

Oral rehydration

Assessment:

Reassess headache score¹ 45 minutes after completion of above interventions



SONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MC



If the headache score decreased to ≤50% of the initial headache score that the nurse obtained upon arrival, and is tolerating PO, then the patient can be prepped for discharge.


The outlined discharge plan is crucial for adequate outpatient management to avoid relapses and returns to ED.

Primary management will be through the PCP, with specific criteria to refer to Neurology or the Pain Team Headache Clinic.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT



CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MD



80079 Connected Challery Health Detect At Springer House 1 Natio

Secondary Interventions:

After the initial management, if the reassessment headache score is not ≤50% of the *initial* headache score obtained upon arrival, further interventions are recommended.

Recent studies show that prochlorperazine is superior to metoclopramide in reducing return visits – and is recommended as a secondary intervention.


Specific criteria for diphenhydramine are given, as recent studies show that it can be associated with return visits.

Adult literature suggests that 10 or 15 mg of ketorolac may be the therapeutic ceiling for analgesia, thus only 1 dose is recommended.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUGGMENT



CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MD






Secondary Interventions:

After completion of all the secondary interventions, wait 45 minutes and reassess the headache score.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CUNICAL AUGMENT



CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, N



Secondary Interventions:

If the reassessment score has improved to be ≤50% of the initial headache score obtained upon arrival, then discharge can be considered.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL SUDGMENT

Indicates Otheria: Nations ago by our percentage with neglaber (190) a long. 2.72 has a voltnet time can of the following durant brinds:

(3) non-original location: (2) plus dating quality in (3) aggressive belte or can expendence for control of the following instances, comiting, photophobia, photophobia, photophobia.

Patients must be on a precision varietably described threadone with trief for our companies the must desire.

[partial calcolombias, non-operated and produce threadone with trief for our companies the must desire.

[partial calcolombias, non-operated distributional photophobia, photophobia, photophobia, photophobia, photophobia distributional distributional distributional distributions of the photophobia.

[partial calcolombias, non-operated distributional distributional distributional distributions of the photophobia distribution distributions.]

[partial calcolombias distribution distr

Intil d Evaluation
Nursing Interventions to occur immediately upon roominated liest.

Determine headache (HA) pain score using Wong Easter FACES Pain Rating Scale or Manaric Pain Rating Scale

Access:


Place PIV

Medications/Hydration:

- NS bolus IV 20 mL/kg (max 1 L) x 1
- Prochlorperazine IV 0.15 mg/kg (max 10 mg) x1
- 6 hours after last NSAID:
 - Ketorolac IV 0.5 mg/kg (max 15 mg) x1
- If patient has extrapyramidal symptoms (dystonia, akathisia, tardive dyskinesia, slurred speech):
 - Consider diphenhydramine PO 1 mg/kg (max 50 mg) x1

Assessment:

Reassess headache score¹ 45 minutes after completion of above interventions



CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MC

DESTRUCTION OF

800 W Technical Character Areas a Carter All Systematics 1 Nation



Tertiary Interventions:

However, if the headache score continues to be elevated after the secondary interventions are complete, tertiary interventions would include repeating the NS bolus and trialing magnesium sulfate.

Again, 45 minutes later, the headache score should be reassessed.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

Industre Orbeita. Palients age 36 years presenting with headadhe (194) lasting 2-72 hears with ut incecome of the following dramatoristics: (1) non-occipital location; (2) polisiting quality, or (3) aggravated by or causing avoidance of routine physical activity AND or least one of the following: name a voroting photophobia, photophobia. Partierts word have a reminer viral pluster obselves adults with railed from community much about Institutional saline halos, non-exercidal anti-inflammatory drug INSA(0), and/or anti-document/capert indusion Otterio: Age obyvers, abnormal neurologic esam, pregramoy, cardiovascalar disease, uncontrolled hapertension, intracrunial duart, lever, maligramoy, no sedite ad who was other 24 hours, concuston within 2 morths, whose, canons to increased intracanal pressure/Cashing That, saddon-creet to abote conting modina intensity within 5-minutes. Intital Evaluation furning interventions to occur immediately upon rooming patient. Determine headache (1944) pain some using Wong Baker (14025 Fain Rating Scale or Numeric Pain Bating Scale tights and TV-off; mesurage not using electronic devices Determine and document last dose of RSAID and accuming Determine and document last dose of any other med Obtain POCT write b-HCG for all live Headache Pain Score Is this reassessment HA score EACES Point tha Scale or But ≤50% of the *initial* headache score∑ Evolute 199 p score di minsafe consistion of each intervention Other Considered one: Discharge gout NO the indistructor Medication/Hydration: Repeat NS bolus 20 mL/kg IV x 1 (max 1L) Magnesium sulfate IV 30 mg/kg (max 2g) Assessment: Reassess headache score 45 minutes after completion of above interventions Encourage PCP refersal to Neurology if: dones/speeds Patient has failed a daily presentative medication for at least Consider diphentrydramene PO 1 mg/kg inva 50 mg/s; Write: "Fer Correction Children's Headache Pathway, pleastrongly consider referral to Preliatric Neurology has our chead ache some 45 minutes, after completion of above interventions fremerage PCP referral to Rain Team Headache Clinic if: If patient has billed two date preventative medications to at feast 12 weeks each OE purkent has been previously. Write: "Per Connectical Children's Headache Palloway **Headache Pain Score** please strong consider referral to Pain Tearn's Headache (Bric Use Wong-Baker **FACES Pain Rating** Scale or Numeric Pain Rating Scale Evaluate HA pain score 45 mins after completion of each intervention Discharge goal: repeat HA pain score is ≤50% of the initial pain score

good ballowing the permanent and party as here as made in the



Tertiary Interventions:

If there is adequate improvement in headache score after the tertiary interventions, the patient may be considered for discharge.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL SUCCESSION

Induses Otheria: Platests ago they are presenting with neutrine (194) using 2-72 has review in corons of the following durative ricks:

(3) new original location; (3) policy quality, in (3) approved they or careing avoidance of routine physical artistry.

(4) at least once of the following: nature, combing, phospholas, phospholas.

Patients much have a president without plate and the address with middle or comparation extends the medications.

Patients much have a president without plate and the address of the

India/Evaluation

- Nursing Interventions to occur insmediately upon rooming patient:


 Determine feradactor (NA) pain score using Wong Saler (ACES Fain Rating Scale or Nameric Pain Rating Scale)
- Lights and EV-off; messurage not using electronic devices
- Oetermine and document last dose of RSAID and acclarate option

Medication/Hydration:

- Repeat NS bolus 20 mL/kg IV x 1 (max 1L)
- Magnesium sulfate IV 30 mg/kg (max 2g)

As ses sment:

• Reassess headache score 45 minutes after completion of above interventions



DNTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIC HOPPA, MC




80079 Television Commercial Systems (Service As Systems on Service) 1 Auto-

If there is no adequate improvement after the tertiary interventions, admission to the inpatient units is warranted for further management.

CLINICAL PATHWAY:

Acute Management of Migraine and Migraine-Like Headache

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CUNICAL SUDGMENT



CONTACTS: RAHUL SHAH, MD | HENRY CHICAIZA, MD | ERIG HOPPA, MC

and the second

800 W Technical Character Areas a Carter All Systematics 1 Nation



Review of Key Points



- Migraines may occur in school-aged children
- Among suggested therapies, intranasal Sumatriptan and NSAIDs have the best evidence of efficacy
- Most recent evidence suggests that:
 - o Prochlorperazine is superior to metoclopramide in reducing return visits
 - Diphenhydramine may be associated with return visits
- Adult literature suggests that 10 or 15 mg of ketorolac may be the therapeutic ceiling for analgesia

Quality Metrics



- Percentage of eligible patients managed per pathway
- Percentage of patients with migraine who are admitted to the hospital
- Rate of return to ED for headache within 48 hours
- Rate of return to ED for headache within 7 days
- Time from arrival to ED to administration of first dose of medication.
- Percentage of patients with neuroimaging during ED visit
- Average time from ED arrival to disposition
- Average pain score at disposition
- Percent change in pain score from time of initial evaluation to time of disposition

Pathway Contacts



- Rahul Shah , MD
 - Pediatric Emergency Medicine Fellow
- Henry Chicaiza, MD
 - Department of Pediatrics; Division of Pediatric Emergency Medicine
- Erica Hoppa, MD
 - o Department of Pediatrics; Division of Pediatric Emergency Medicine

References



- Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. *Pediatrics*. 2015 Feb;135(2):232-8.
- Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. *Pediatr Neurol.* 2012;47(4):233-41.
- Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9(2):190-204.
- Kaar CR, Gerard JM, Nakanishi AK. The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting. *Pediatr Emerg Care*. 2016 Jul;32(7):435-9.
- Kabbouche M. Management of Pediatric Migraine Headache in the Emergency Room and Infusion Center. Headache. 2015;55(10): 1365-70.
- Kanis JM, Timm NL. Chlorpromazine for the treatment of migraine in a pediatric emergency department. *Headache*. 2014;54(2):335-42.
- Leung S, Bulloch B, Young C, et al. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013 Mar;53(3):491-97.
- Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. *Neurology*. 2004;63(12):2215-24.
- Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 Sep;93(11):487-499.
- Patniyot IR, Gelfand AA. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache. 2016;56(1):49-70.
- Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: national practice variation study. *Pediatrics*. 2010;126(1):e150-5.
- Skora CE, Worden LT, Oakley CB. Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes. *J Child Neurol*. 2020 Mar;35(3)235-241.
- Teleanu RI, Vladacenco O, Teleanu DM, et al. Treatment of Pediatric Migraine: a Review. Maedica (Buchar). 2016;11(2):136-143.

Thank You!



About Connecticut Children's Clinical Pathways Program

The Clinical Pathways Program at Connecticut Children's aims to improve the quality of care our patients receive, across both ambulatory and acute care settings. We have implemented a standardized process for clinical pathway development and maintenance to ensure meaningful improvements to patient care as well as systematic continual improvement. Development of a clinical pathway includes a multidisciplinary team, which may include doctors, advanced practitioners, nurses, pharmacists, other specialists, and even patients/families. Each clinical pathway has a flow algorithm, an educational module for end-user education, associated order set(s) in the electronic medical record, and quality metrics that are evaluated regularly to measure the pathway's effectiveness. Additionally, clinical pathways are reviewed annually and updated to ensure alignment with the most up to date evidence. These pathways serve as a guide for providers and do not replace clinical judgment.